TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques - PubMed (original) (raw)
TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques
Alice B Gottlieb et al. J Immunol. 2005.
Abstract
The mechanisms of action of marketed TNF-blocking drugs in lesional tissues are still incompletely understood. Because psoriasis plaques are accessible to repeat biopsy, the effect of TNF/lymphotoxin blockade with etanercept (soluble TNFR) was studied in ten psoriasis patients treated for 6 months. Histological response, inflammatory gene expression, and cellular infiltration in psoriasis plaques were evaluated. There was a rapid and complete reduction of IL-1 and IL-8 (immediate/early genes), followed by progressive reductions in many other inflammation-related genes, and finally somewhat slower reductions in infiltrating myeloid cells (CD11c+ cells) and T lymphocytes. The observed decreases in IL-8, IFN-gamma-inducible protein-10 (CXCL10), and MIP-3alpha (CCL20) mRNA expression may account for decreased infiltration of neutrophils, T cells, and dendritic cells (DCs), respectively. DCs may be less activated with therapy, as suggested by decreased IL-23 mRNA and inducible NO synthase mRNA and protein. Decreases in T cell-inflammatory gene expression (IFN-gamma, STAT-1, granzyme B) and T cell numbers may be due to a reduction in DC-mediated T cell activation. Thus, etanercept-induced TNF/lymphotoxin blockade may break the potentially self-sustaining cycle of DC activation and maturation, subsequent T cell activation, and cytokine, growth factor, and chemokine production by multiple cell types including lymphocytes, neutrophils, DCs, and keratinocytes. This results in reversal of the epidermal hyperplasia and cutaneous inflammation characteristic of psoriatic plaques.
Similar articles
- Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes.
Zaba LC, Suárez-Fariñas M, Fuentes-Duculan J, Nograles KE, Guttman-Yassky E, Cardinale I, Lowes MA, Krueger JG. Zaba LC, et al. J Allergy Clin Immunol. 2009 Nov;124(5):1022-10.e1-395. doi: 10.1016/j.jaci.2009.08.046. J Allergy Clin Immunol. 2009. PMID: 19895991 Free PMC article. Clinical Trial. - Mechanisms of action of etanercept in psoriasis.
Tan JK, Aphale A, Malaviya R, Sun Y, Gottlieb AB. Tan JK, et al. J Investig Dermatol Symp Proc. 2007 May;12(1):38-45. doi: 10.1038/sj.jidsymp.5650037. J Investig Dermatol Symp Proc. 2007. PMID: 17502868 Review. - Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24.
Wang F, Smith N, Maier L, Xia W, Hammerberg C, Chubb H, Chen C, Riblett M, Johnston A, Gudjonsson JE, Helfrich Y, Kang S, Fisher GJ, Voorhees JJ. Wang F, et al. Br J Dermatol. 2012 Jul;167(1):92-102. doi: 10.1111/j.1365-2133.2012.10961.x. Br J Dermatol. 2012. PMID: 22458549 - Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation.
Johnston A, Fritz Y, Dawes SM, Diaconu D, Al-Attar PM, Guzman AM, Chen CS, Fu W, Gudjonsson JE, McCormick TS, Ward NL. Johnston A, et al. J Immunol. 2013 Mar 1;190(5):2252-62. doi: 10.4049/jimmunol.1201505. Epub 2013 Jan 28. J Immunol. 2013. PMID: 23359500 Free PMC article. - [TNF alpha in the physiopathology of psoriasis].
Rozieres A, Hennino A, Nicolas JF. Rozieres A, et al. Ann Dermatol Venereol. 2006 Feb;133(2):174-80. doi: 10.1016/s0151-9638(06)70873-0. Ann Dermatol Venereol. 2006. PMID: 16508606 Review. French. No abstract available.
Cited by
- Exploring shared mechanisms between ulcerative colitis and psoriasis and predicting therapeutic natural compounds through bioinformatics and molecular docking.
Yang Y, Gong Z, Yang J, Cai Y, Hong S, Mao W, Guo Z, Qiu M, Fan Z, Cui B. Yang Y, et al. Heliyon. 2024 Sep 7;10(18):e37624. doi: 10.1016/j.heliyon.2024.e37624. eCollection 2024 Sep 30. Heliyon. 2024. PMID: 39309918 Free PMC article. - Psoriasis and Psoriatic Arthritis-Associated Genes, Cytokines, and Human Leukocyte Antigens.
Zalesak M, Danisovic L, Harsanyi S. Zalesak M, et al. Medicina (Kaunas). 2024 May 16;60(5):815. doi: 10.3390/medicina60050815. Medicina (Kaunas). 2024. PMID: 38792999 Free PMC article. Review. - Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double-blinded clinical trial.
Mohammadi F, Harofteh FZ, Sahebnasagh A, Ghaneei N, Ardakani MEZ, Saghafi F. Mohammadi F, et al. Skin Res Technol. 2024 Apr;30(4):e13689. doi: 10.1111/srt.13689. Skin Res Technol. 2024. PMID: 38563131 Free PMC article. Clinical Trial. - Anti-Atopic Dermatitis Effect of TPS240, a Novel Therapeutic Peptide, via Suppression of NF-κB and STAT3 Activation.
Lee D, Hwang-Bo J, Veerappan K, Moon H, Park J, Chung H. Lee D, et al. Int J Mol Sci. 2023 Oct 31;24(21):15814. doi: 10.3390/ijms242115814. Int J Mol Sci. 2023. PMID: 37958804 Free PMC article. - CREB1-driven CXCR4hi neutrophils promote skin inflammation in mouse models and human patients.
Chen J, Bai Y, Xue K, Li Z, Zhu Z, Li Q, Yu C, Li B, Shen S, Qiao P, Li C, Luo Y, Qiao H, Dang E, Yin W, Gudjonsson JE, Wang G, Shao S. Chen J, et al. Nat Commun. 2023 Sep 22;14(1):5894. doi: 10.1038/s41467-023-41484-3. Nat Commun. 2023. PMID: 37736772 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous